WO2020107015A1 - Application of binary naltrexone derivatives - Google Patents

Application of binary naltrexone derivatives

Info

Publication number
WO2020107015A1
WO2020107015A1 PCT/US2019/062808 US2019062808W WO2020107015A1 WO 2020107015 A1 WO2020107015 A1 WO 2020107015A1 US 2019062808 W US2019062808 W US 2019062808W WO 2020107015 A1 WO2020107015 A1 WO 2020107015A1
Authority
WO
WIPO (PCT)
Prior art keywords
binary
formula
naltrexone
application
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/062808
Other languages
French (fr)
Inventor
Xiahui Wang
Linda R. Watkins
Matthew D. METCALF
Phillip PORTOGHESE
Kenner C. Rice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
National Institutes of Health NIH
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
University of Minnesota Twin Cities
National Institutes of Health NIH
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, National Institutes of Health NIH, University of Colorado System, University of Colorado Colorado Springs filed Critical University of Minnesota Twin Cities
Publication of WO2020107015A1 publication Critical patent/WO2020107015A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the field of medical technology, especially to applications involving binary naltrexone derivatives.
  • TLR4 Toll-like receptor 4
  • PAMPs pathogen-associated molecular patterns
  • DAMPs endogenous damage-associated molecular patterns
  • XAMPs xenobiotic-associated molecular patterns
  • the immune response protects the body, but a persistent inflammatory response can cause damage to the body.
  • the abnormality of the innate immune TLR4 signaling pathway is closely related to the molecular causes of many diseases, such as autoimmune diseases (systemic lupus erythematosus and rheumatoid arthritis), cancer (lung cancer, breast cancer, and ovarian cancer), and cardiovascular diseases. Therefore, small molecule modulators targeting TLR4 and its accessory protein MD-2 have been extensively studied.
  • narcotics such as morphine, cocaine, and methamphetamine act as xenobiotics, activate microglia through the natural immune receptor TLR4, produce a large number of inflammatory factors, enhance neuronal excitability, and lead to drag dependence and addiction.
  • TLR4 signaling pathway abnormalities in the TLR4 signaling pathway are also associated with molecular mechanisms of dmg addiction and neuropathic pain.
  • abnormalities in the TLR4 signaling pathway are also associated with molecular mechanisms of dmg addiction and neuropathic pain.
  • naltrexone inhibits lipopolysaccharides (LPS)-induced gene expression in HEK-TLR4 cells, and the (+) and (-) configuration enantiomers exhibit very similar inhibitory effects.
  • LPS lipopolysaccharides
  • naltrexone and its derivatives have good blood-brain barrier permeability.
  • (+)-naltrexone has good dmg compliance, universality, and synergy, though (+)- naltrexone has low inhibitory activity on TLR4 and has no stereoselectivity.
  • the technical problem to be solved by the present invention is to provide the application of binary naltrexone derivatives.
  • the present invention experimentally found that binary naltrexone derivatives can be used to inhibit the TLR4 signaling pathway, thereby inhibiting the expression of inflammatory factors.
  • the present invention provides an application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors.
  • the present invention provides an application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors.
  • the inflammatory factor comprises one or more of TNF-a and IL-1B.
  • the present invention provides the application of binary naltrexone derivatives in the preparation of inflammatory signaling pathway activation inhibitors.
  • the inhibitors are used to inhibit activation of TLR4 signaling pathways, the expression of inflammatory factors, or the release of nitric oxide by LPS.
  • the binary naltrexone derivatives are as shown in formula (I), formula (II) or formula (III).
  • the present invention provides an application of binary naltrexone derivatives in the preparation of drags for the prevention of autoimmune diseases, cancers, cardiovascular disease, drag addiction, or neuropathic pain.
  • the autoimmune diseases include systemic lupus erythematosus, and rheumatoid arthritis
  • the cancers include lung cancer, breast cancer, and ovarian cancer.
  • the present invention provides a drag for controlling an autoimmune disease, cancer, cardiovascular disease, drag addiction, or neuropathic pain, which comprises a binary naltrexone derivative and a pharmaceutically acceptable excipient.
  • the pharmaceutical dosage form comprises one of an injection preparation, an oral preparation, and a spray preparation.
  • the present invention provides the application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors. It also provides the application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors, binary naltrexone.
  • the derivatives are used in the preparation of inflammatory signaling pathway activation inhibitors.
  • the present invention confirmed in vitro that the levels of nitric oxide and downstream inflammatory factors were significantly increased in glial cells activated by lipopolysaccharides (LPS).
  • Binary naltrexone derivatives significantly inhibited the release of nitric oxide and the expression of downstream inflammatory factors.
  • the inhibitory activities of TLR4 were for formula
  • Figure 1 depicts the inhibitory effect of binary naltrexone derivatives formula (II) on the activation of TLR4 signaling pathway in BV-2 microglia in embodiment 1 of the present invention.
  • Figure 2 depicts the inhibitory effect of binary naltrexone derivatives formula (III) in TLR4 signaling pathway activation in BV-2 microglia in embodiment 1 of the present invention.
  • Figure 3 depicts the inhibitory effect of inflammatory factor TNF-a expression in BV-2 microglia in embodiment 2 of the present invention.
  • Figure 4 depicts the inhibitory effect of binary naltrexone derivatives formula (II) in inflammatory factor IL-1B expression in BV-2 microglia in embodiment 2 of the present invention.
  • Figure 5 depicts the inhibitory effect of binary naltrexone derivatives formula (II) in TLR4 signaling pathway activation in primary microglia in embodiment 3 of the present invention.
  • Figure 6 depicts the effect of binary naltrexone derivatives formula (II) in inflammatory factor TNF-a expression in primary microglia in embodiment 4 of the present invention.
  • Figure 7 depicts the inhibitory effect of binary naltrexone derivatives formula (II) in TLR4 signaling pathway activation in primary astrocytes in embodiment 5 of the present invention.
  • Figure 8 depicts the effect of binary naltrexone derivatives formula (II) in inflammatory factor TNF-a expression in primary astrocytes in embodiment 6 of the present invention.
  • the present invention provides an application of the binary naltrexone derivatives, and those skilled in the art can refer to the contents of this document and improve it as appropriate. It is to be noted that all similar substitutions and modifications will be apparent to those skilled in the art. They all fall within the scope of the present invention.
  • the method and application of the present invention have been described in the preferred embodiments, and it is obvious that the method and application of the present invention can be modified or combined and modified to achieve and use the present invention without departing from the content, spirit, and scope of the technology of the present invention.
  • the present invention provides the application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors.
  • the inhibitors are preferably used to inhibit TLR4 signaling pathway activation by LPS.
  • the TLR4 described in the present invention preferably has a primary expression in BV-2 microglia, primary microglia, or primary astrocytes.
  • binary naltrexone derivatives of the present invention are shown as formula (I), formula (II) or formula (III); preferably, the structure is as shown in formula II or formula I
  • the present invention is not limited in its source, and is commercially available or prepared according to a conventional method of the prior art.
  • the preparation method of the compound of the present invention is preferably according to the literature (Portoghese, PS; Nagase, H.; Takemori, AE Stereochemical Studies on 31. Only One Pharmacophore Is Required for the K-Opioid Antagonist Selectivity of Norbinaltorphimine. Journal of Medicinal Chemistry, 31 (1988), 1344-1347).
  • TLR4 can recognize inflammatory immune responses induced by exogenous pathogen-associated molecular patterns (PAMPs), endogenous damage-associated molecular patterns (DAMPs), and xenobiotic -associated molecular patterns (XAMPs).
  • PAMPs pathogen-associated molecular patterns
  • DAMPs endogenous damage-associated molecular patterns
  • XAMPs xenobiotic -associated molecular patterns
  • the immune response can protect the body, but the persistent inflammatory response can cause damage to the body.
  • the natural immune TLR4 signaling pathway abnormalities are closely related to the molecular causes of many diseases, such as autoimmune diseases (systemic lupus erythematosus and rheumatoid arthritis), cancers (lung cancer, breast cancer, and ovarian cancer) and cardiovascular diseases.
  • the prior art discloses the activation of microglia by the natural immune receptor TLR4, which produces a large number of inflammatory factors and enhances neuronal excitability, resulting in a pharmaceutical dependence and addiction.
  • binary naltrexone derivatives have significant inhibitory effects on the natural immune receptor TLR4-mediated signaling pathways. Moreover, different binary naltrexone derivatives showed different inhibitory activities against TLR4-mediated signaling pathways.
  • TLR4 inhibitory activity was for formula (II) (4.7 ⁇ 0.48 mM) and formula (III) (6.23 ⁇ 1.82 pM), meaning that binary naltrexone derivatives played a key role in the natural immune receptor TLR4-mediated immune response.
  • formula (II) and formula (III) showed selectivity during the inhibition of TLR4 signaling pathways.
  • the present invention provides the application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors.
  • the inflammatory factor described in the present invention preferably includes one or more of TNF-a and IL-1B.
  • the inhibitors are preferably used to inhibit inflammatory factor expression or nitric oxide release by LPS.
  • the present invention confirmed by in vitro experiments that the levels of nitric oxide and downstream inflammatory factors were significantly increased in glial cells treated with lipopolysaccharides (LPS). Binary naltrexone derivatives significantly inhibited the release of nitric oxide and the expression of downstream inflammatory factors.
  • LPS lipopolysaccharides
  • the present invention also provides the application of binary naltrexone derivatives in the preparation of inhibitors of inflammatory signaling pathways.
  • the described inhibitors are used to inhibit TLR4 pathway activation, inflammatory factor expression or nitric oxide release caused by LPS.
  • the present invention experimentally confirmed that the binary naltrexone derivatives can significantly inhibit the release of nitric oxide and the expression of downstream inflammatory factors, thus confirming that binary naltrexone derivatives can inhibit the activation of signaling pathways.
  • binary naltrexone derivatives of the present invention are shown as formula (I), formula (II) or formula (III); preferably, the structure is as shown in formula (II) or formula (III).
  • the binary naltrexone derivatives of the formula (I) structure may be labeled as (-)-l, and the binary naltrexone derivatives of the formula (II) structure may be labeled as (+)-l; the binary naltrexone derivatives of the formula (III) structure may be labeled as 2.
  • the present invention is not limited in its source, and is commercially available or prepared according to a conventional method of the prior art.
  • the preparation method of the compound of the present invention is preferably according to the literature (Portoghese, PS; Nagase, H.; Takemori, AE Stereochemical Studies on 31. Only One Pharmacophore Is Required for the K-Opioid Antagonist Selectivity of Norbinaltorphimine. Journal of Medicinal Chemistry, 31 (1988), 1344-1347).
  • the present invention provides application of binary naltrexone derivatives in the preparation of drags for the prevention of autoimmune diseases, cancers, or cardiovascular disease.
  • the autoimmune diseases in the present invention include systemic lupus erythematosus, and rheumatoid arthritis, and the cancers include lung cancer, breast cancer, and ovarian cancer
  • the present invention finds that binary naltrexone derivatives can reduce drag dependence and addiction by inhibiting the TLR4 signaling pathway. This invention will provide an effective therapeutic approach for drag addiction and neuropathic pain.
  • the present invention provides a drag for controlling autoimmune disease, cancer, cardiovascular disease, drag addiction, or neuropathic pain, which comprises a binary naltrexone derivative and a pharmaceutically acceptable excipient.
  • the dosage form of the drag described in the present invention comprises one of an injection preparation, an oral preparation, and a spray preparation.
  • the present invention is not limited to the pharmaceutically acceptable excipients, and is well known to those skilled in the art.
  • the present invention also provides the application of binary naltrexone derivatives in the preparation of health products for improving autoimmune diseases, cancer, or cardiovascular diseases.
  • the present invention provides the application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors.
  • the present invention also provides the application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors and the application of binary naltrexone derivatives in the preparation of inflammatory signaling pathway activation inhibitors.
  • the present invention confirmed by in vivo experiments that the levels of nitric oxide and downstream inflammatory factors were significantly increased in glial cells activated by lipopolysaccharides (LPS), such that binary naltrexone derivatives can significantly inhibit the release of nitric oxide and the expression of downstream inflammatory factors.
  • LPS lipopolysaccharides
  • the inhibitory activities of TLR4 were formula (II) (4.7 ⁇ 0.48 mM) and formula (III) (6.23 ⁇ 1.82 pM).
  • Formula (I) has no significant inhibitory effect. This means that binary naltrexone derivatives play a key role in the natural immune receptor TLR4-mediated immune response, and formula (II) and formula (III) show selectivity during the inhibition of TLR4 signaling pathway.
  • the compound binary naltrexone derivatives of the present invention have good blood-brain barrier permeability. Experimental data indicate that binary naltrexone derivatives formula (II) or formula (III) play an important role in the natural immune receptor TLR4-mediated immune response and are considered to be the major TLR4 signaling pathway inhibitors.
  • the present invention can increase TLR4 inhibitor activity and stereostructural selectivity. This will provide an effective therapeutic approach for drag addiction and neuropathic pain.
  • BV-2 microglia were cultured in an incubator at 37°C (containing 5% carbon dioxide).
  • BV-2 microglia were resuspended in medium (cell density: 2 MO 5 cells/ml), plate in 96-well plate overnight.
  • Embodiment 1 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are shown in Figure 1 and Figure 2, where Figure 1 depicts the inhibitory effect of binary naltrexone derivatives on the activation of the TLR4 signaling pathway in BV-2 microglia in embodiment 1 of the present invention; Figure 2 depicts the inhibitory effect of binary naltrexone derivatives on the activation of the TLR4 signaling pathway in BV-2 microglia in embodiment 1 of the present invention.
  • the inhibitors formula (II) and formula (III) can inhibit the release of nitric oxide, and the inhibitory activities are for formula (II) (4.7 ⁇ 0.48 mM) and formula (III) (6.23 ⁇ 1.82mM).
  • Formula (I) has no significant inhibitory activity.
  • BV-2 microglia were cultured in an incubator at 37°C (containing 5% carbon dioxide).
  • BV-2 microglia resuspended in medium (cell density: 2 MO 5 cells/ml), plate in 96-well plate overnight.
  • Embodiment 2 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are as shown in Figure 3 and Figure 4, where Figure 3 depicts the inhibitory effect of binary naltrexone derivatives on inflammatory factor TNF-a expression in BV-2 microglia in embodiment 2 of the present invention
  • Figure 4 depicts the inhibitory effect of binary naltrexone derivatives on inflammatory factor IL-1B expression in BV-2 microglia in embodiment 2 of the present invention.
  • inhibitor formula (II) described in the present invention can significantly inhibit inflammatory factor expression.
  • Formula (I) has no significant inhibitory effect.
  • Embodiment 3 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are as shown in Figure 5, where Figure 5 depicts the inhibitory effect of binary naltrexone derivatives on TLR4 signaling pathway activation in primary microglia in embodiment 3 of the present invention;
  • inhibitor (II) described in the present invention can significantly inhibit nitric oxide release.
  • Formula (I) has no significant inhibitory activity.
  • Embodiment 4 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives.
  • Figure 6 depicts the effect of binary naltrexone derivatives on inflammatory factor TNF-a expression in primary microglia in embodiment 4 of the present invention.
  • the inhibitor formula (II) described in the present invention can significantly inhibit inflammatory factor expression.
  • Formula (I) has no significant inhibitory effect.
  • Embodiment 5 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are as shown in Figure 7.
  • Figure 7 depicts the inhibitory effect of binary naltrexone derivatives formula (II) on TLR4 signaling pathway activation in primary astrocytes in embodiment 5 of the present invention.
  • the inhibitor formula (II) described in the present invention can significantly inhibit the release of nitric oxide.
  • Formula (I) has no significant inhibitory activity.
  • Embodiment 6 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are as shown in Figure 8.
  • Figure 8 depicts the effect of binary naltrexone derivatives formula (II) on inflammatory factor TNF-a expression in primary astrocytes in embodiment 6 of the present invention.
  • inhibitor formula (II) described in the present invention can significantly inhibit inflammatory factor expression.
  • Formula (I) has no significant inhibitory effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides the application of binary naltrexone derivatives in the preparation of Toll-like receptor 4 signaling pathway inhibitors, the application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors, and the application of binary naltrexone derivatives in the preparation of inhibitors of inflammatory signaling pathways. It has been confirmed in vitro that the levels of nitric oxide and downstream inflammatory factors are significantly elevated in glial cells activated by lipopolysaccharides (LPS). Binary naltrexone derivatives significantly inhibited the release of nitric oxide and the expression of downstream inflammatory factors. Binary naltrexone derivatives significantly inhibited the release of nitric oxide and the expression of downstream inflammatory factors. Toll-like receptor 4 inhibitory activities were formula (II) (4.7 ± 0.48 μΜ) and formula (III) (6.23 ± 1.82 μΜ). Binary naltrexone derivatives play a key role in the innate immune receptor Toll-like receptor 4 mediated immune response, and formula (II) and formula (III) exhibit sputum selectivity during the inhibition of Toll-like receptor 4 signaling pathways.

Description

Application of binary naltrexone derivatives
Technical Field
[0001] The present invention relates to the field of medical technology, especially to applications involving binary naltrexone derivatives.
Background Techniques
[0002] Toll-like receptor 4 (TLR4), a typical innate immune receptor, recognizes inflammatory immune response induced by exogenous pathogen-associated molecular patterns (PAMPs), endogenous damage-associated molecular patterns (DAMPs), and xenobiotic-associated molecular patterns (XAMPs). The immune response protects the body, but a persistent inflammatory response can cause damage to the body. Among them, the abnormality of the innate immune TLR4 signaling pathway is closely related to the molecular causes of many diseases, such as autoimmune diseases (systemic lupus erythematosus and rheumatoid arthritis), cancer (lung cancer, breast cancer, and ovarian cancer), and cardiovascular diseases. Therefore, small molecule modulators targeting TLR4 and its accessory protein MD-2 have been extensively studied.
[0003] A series of recent studies have found that narcotics such as morphine, cocaine, and methamphetamine act as xenobiotics, activate microglia through the natural immune receptor TLR4, produce a large number of inflammatory factors, enhance neuronal excitability, and lead to drag dependence and addiction. These data suggest that abnormalities in the TLR4 signaling pathway are also associated with molecular mechanisms of dmg addiction and neuropathic pain. These data suggest that abnormalities in the TLR4 signaling pathway are also associated with molecular mechanisms of dmg addiction and neuropathic pain. Recent studies have shown that naltrexone inhibits lipopolysaccharides (LPS)-induced gene expression in HEK-TLR4 cells, and the (+) and (-) configuration enantiomers exhibit very similar inhibitory effects. In addition, naltrexone and its derivatives have good blood-brain barrier permeability. Among them, (+)-naltrexone has good dmg compliance, universality, and synergy, though (+)- naltrexone has low inhibitory activity on TLR4 and has no stereoselectivity.
[0004] Therefore, it is very necessary to develop an inhibitor with high TLR4 inhibitory activity.
Content of Invention
[0005] In view of this, the technical problem to be solved by the present invention is to provide the application of binary naltrexone derivatives. The present invention experimentally found that binary naltrexone derivatives can be used to inhibit the TLR4 signaling pathway, thereby inhibiting the expression of inflammatory factors.
[0006] The present invention provides an application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors.
[0007] The present invention provides an application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors.
[0008] Preferably, the inflammatory factor comprises one or more of TNF-a and IL-1B.
[0009] The present invention provides the application of binary naltrexone derivatives in the preparation of inflammatory signaling pathway activation inhibitors.
[0010] Preferably, the inhibitors are used to inhibit activation of TLR4 signaling pathways, the expression of inflammatory factors, or the release of nitric oxide by LPS.
[0011] Preferably, the binary naltrexone derivatives are as shown in formula (I), formula (II) or formula (III).
Figure imgf000004_0001
Formula (II) imnt
Figure imgf000004_0002
Formula (III)
[0013] The present invention provides an application of binary naltrexone derivatives in the preparation of drags for the prevention of autoimmune diseases, cancers, cardiovascular disease, drag addiction, or neuropathic pain.
[0014] Preferably, the autoimmune diseases include systemic lupus erythematosus, and rheumatoid arthritis, and the cancers include lung cancer, breast cancer, and ovarian cancer.
[0015] The present invention provides a drag for controlling an autoimmune disease, cancer, cardiovascular disease, drag addiction, or neuropathic pain, which comprises a binary naltrexone derivative and a pharmaceutically acceptable excipient.
[0016] Preferably, the pharmaceutical dosage form comprises one of an injection preparation, an oral preparation, and a spray preparation.
[0017] Compared to the prior art, the present invention provides the application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors. It also provides the application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors, binary naltrexone. The derivatives are used in the preparation of inflammatory signaling pathway activation inhibitors. The present invention confirmed in vitro that the levels of nitric oxide and downstream inflammatory factors were significantly increased in glial cells activated by lipopolysaccharides (LPS). Binary naltrexone derivatives significantly inhibited the release of nitric oxide and the expression of downstream inflammatory factors. The inhibitory activities of TLR4 were for formula
(II) (4.7 ± 0.48 mM) and for formula (III) (6.23 ± 1.82 mM), respectively. Formula (I) has no significant inhibitory effect. This means that binary naltrexone derivatives play a key role in the innate immune receptor TLR4 mediated immune response and inhibit the TLR4 signaling pathway, with selectivity indicated in formula (II) and formula
(III).
Description of Attached Figures
[0018] Figure 1 depicts the inhibitory effect of binary naltrexone derivatives formula (II) on the activation of TLR4 signaling pathway in BV-2 microglia in embodiment 1 of the present invention.
[0019] Figure 2 depicts the inhibitory effect of binary naltrexone derivatives formula (III) in TLR4 signaling pathway activation in BV-2 microglia in embodiment 1 of the present invention.
[0020] Figure 3 depicts the inhibitory effect of inflammatory factor TNF-a expression in BV-2 microglia in embodiment 2 of the present invention.
[0021] Figure 4 depicts the inhibitory effect of binary naltrexone derivatives formula (II) in inflammatory factor IL-1B expression in BV-2 microglia in embodiment 2 of the present invention.
[0022] Figure 5 depicts the inhibitory effect of binary naltrexone derivatives formula (II) in TLR4 signaling pathway activation in primary microglia in embodiment 3 of the present invention. Cb
[0023] Figure 6 depicts the effect of binary naltrexone derivatives formula (II) in inflammatory factor TNF-a expression in primary microglia in embodiment 4 of the present invention.
[0024] Figure 7 depicts the inhibitory effect of binary naltrexone derivatives formula (II) in TLR4 signaling pathway activation in primary astrocytes in embodiment 5 of the present invention.
[0025] Figure 8 depicts the effect of binary naltrexone derivatives formula (II) in inflammatory factor TNF-a expression in primary astrocytes in embodiment 6 of the present invention.
Detailed Description of the Preferred Embodiments
[0026] The present invention provides an application of the binary naltrexone derivatives, and those skilled in the art can refer to the contents of this document and improve it as appropriate. It is to be noted that all similar substitutions and modifications will be apparent to those skilled in the art. They all fall within the scope of the present invention. The method and application of the present invention have been described in the preferred embodiments, and it is obvious that the method and application of the present invention can be modified or combined and modified to achieve and use the present invention without departing from the content, spirit, and scope of the technology of the present invention.
[0027] The present invention provides the application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors.
[0028] According to the present invention, the inhibitors are preferably used to inhibit TLR4 signaling pathway activation by LPS.
[0029] The TLR4 described in the present invention preferably has a primary expression in BV-2 microglia, primary microglia, or primary astrocytes.
[0030] The binary naltrexone derivatives of the present invention are shown as formula (I), formula (II) or formula (III); preferably, the structure is as shown in formula II or formula I
Figure imgf000005_0001
Figure imgf000005_0002
Formula (II)
[0031]
Figure imgf000005_0003
Formula (III)
[0032] The present invention is not limited in its source, and is commercially available or prepared according to a conventional method of the prior art. The preparation method of the compound of the present invention is preferably according to the literature (Portoghese, PS; Nagase, H.; Takemori, AE Stereochemical Studies on 31. Only One Pharmacophore Is Required for the K-Opioid Antagonist Selectivity of Norbinaltorphimine. Journal of Medicinal Chemistry, 31 (1988), 1344-1347). [0033] As a typical natural immune receptor, TLR4 can recognize inflammatory immune responses induced by exogenous pathogen-associated molecular patterns (PAMPs), endogenous damage-associated molecular patterns (DAMPs), and xenobiotic -associated molecular patterns (XAMPs). The immune response can protect the body, but the persistent inflammatory response can cause damage to the body. Among them, the natural immune TLR4 signaling pathway abnormalities are closely related to the molecular causes of many diseases, such as autoimmune diseases (systemic lupus erythematosus and rheumatoid arthritis), cancers (lung cancer, breast cancer, and ovarian cancer) and cardiovascular diseases.
[0034] The prior art discloses the activation of microglia by the natural immune receptor TLR4, which produces a large number of inflammatory factors and enhances neuronal excitability, resulting in a pharmaceutical dependence and addiction.
[0035] The inventor experimentally confirmed that binary naltrexone derivatives play an important role in the immune response mediated by the natural immune receptor TLR4 and are the major TLR4 signaling pathway inhibitors.
[0036] Through in vivo natural immune pathway activation signal nitric oxide and downstream inflammatory factor assay, the present invention found that binary naltrexone derivatives have significant inhibitory effects on the natural immune receptor TLR4-mediated signaling pathways. Moreover, different binary naltrexone derivatives showed different inhibitory activities against TLR4-mediated signaling pathways.
[0037] The present invention confirmed by experiments that TLR4 inhibitory activity was for formula (II) (4.7 ± 0.48 mM) and formula (III) (6.23 ± 1.82 pM), meaning that binary naltrexone derivatives played a key role in the natural immune receptor TLR4-mediated immune response. Moreover, formula (II) and formula (III) showed selectivity during the inhibition of TLR4 signaling pathways.
[0038] The present invention provides the application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors.
[0039] The inflammatory factor described in the present invention preferably includes one or more of TNF-a and IL-1B.
[0040] According to the present invention, the inhibitors are preferably used to inhibit inflammatory factor expression or nitric oxide release by LPS.
[0041] The inventor experimentally confirmed that the inhibitors formula (II) and formula (III) described by the present invention significantly inhibited the release of nitric oxide, and the inhibitory activities for formula (II) and (III) were (4.7 ± 0.48 pM) and (6.23 ± 1.82 pM), respectively.
[0042] The present invention confirmed by in vitro experiments that the levels of nitric oxide and downstream inflammatory factors were significantly increased in glial cells treated with lipopolysaccharides (LPS). Binary naltrexone derivatives significantly inhibited the release of nitric oxide and the expression of downstream inflammatory factors.
[0043] The present invention also provides the application of binary naltrexone derivatives in the preparation of inhibitors of inflammatory signaling pathways.
[0044] According to the present invention, the described inhibitors are used to inhibit TLR4 pathway activation, inflammatory factor expression or nitric oxide release caused by LPS.
[0045] The present invention experimentally confirmed that the binary naltrexone derivatives can significantly inhibit the release of nitric oxide and the expression of downstream inflammatory factors, thus confirming that binary naltrexone derivatives can inhibit the activation of signaling pathways.
[0046] The binary naltrexone derivatives of the present invention are shown as formula (I), formula (II) or formula (III); preferably, the structure is as shown in formula (II) or formula (III).
Figure imgf000007_0001
ormu a ( )
[0048] The binary naltrexone derivatives of the formula (I) structure may be labeled as (-)-l, and the binary naltrexone derivatives of the formula (II) structure may be labeled as (+)-l; the binary naltrexone derivatives of the formula (III) structure may be labeled as 2.
[0049] The present invention is not limited in its source, and is commercially available or prepared according to a conventional method of the prior art. The preparation method of the compound of the present invention is preferably according to the literature (Portoghese, PS; Nagase, H.; Takemori, AE Stereochemical Studies on 31. Only One Pharmacophore Is Required for the K-Opioid Antagonist Selectivity of Norbinaltorphimine. Journal of Medicinal Chemistry, 31 (1988), 1344-1347).
[0050] The present invention provides application of binary naltrexone derivatives in the preparation of drags for the prevention of autoimmune diseases, cancers, or cardiovascular disease.
[0051] The autoimmune diseases in the present invention include systemic lupus erythematosus, and rheumatoid arthritis, and the cancers include lung cancer, breast cancer, and ovarian cancer
[0052] Since the abnormality of the TLR4 signaling pathway is also related to the molecular mechanism of drag addiction and neuropathic pain, the present invention finds that binary naltrexone derivatives can reduce drag dependence and addiction by inhibiting the TLR4 signaling pathway. This invention will provide an effective therapeutic approach for drag addiction and neuropathic pain.
[0053] The present invention provides a drag for controlling autoimmune disease, cancer, cardiovascular disease, drag addiction, or neuropathic pain, which comprises a binary naltrexone derivative and a pharmaceutically acceptable excipient.
[0054] The dosage form of the drag described in the present invention comprises one of an injection preparation, an oral preparation, and a spray preparation. The present invention is not limited to the pharmaceutically acceptable excipients, and is well known to those skilled in the art.
[0055] The present invention also provides the application of binary naltrexone derivatives in the preparation of health products for improving autoimmune diseases, cancer, or cardiovascular diseases.
[0056] The present invention provides the application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors. The present invention also provides the application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors and the application of binary naltrexone derivatives in the preparation of inflammatory signaling pathway activation inhibitors. The present invention confirmed by in vivo experiments that the levels of nitric oxide and downstream inflammatory factors were significantly increased in glial cells activated by lipopolysaccharides (LPS), such that binary naltrexone derivatives can significantly inhibit the release of nitric oxide and the expression of downstream inflammatory factors. The inhibitory activities of TLR4 were formula (II) (4.7 ± 0.48 mM) and formula (III) (6.23 ± 1.82 pM). Formula (I) has no significant inhibitory effect. This means that binary naltrexone derivatives play a key role in the natural immune receptor TLR4-mediated immune response, and formula (II) and formula (III) show selectivity during the inhibition of TLR4 signaling pathway. [0057] The compound binary naltrexone derivatives of the present invention have good blood-brain barrier permeability. Experimental data indicate that binary naltrexone derivatives formula (II) or formula (III) play an important role in the natural immune receptor TLR4-mediated immune response and are considered to be the major TLR4 signaling pathway inhibitors. The present invention can increase TLR4 inhibitor activity and stereostructural selectivity. This will provide an effective therapeutic approach for drag addiction and neuropathic pain.
[0058] To further illustrate the present invention, the applications of the binary naltrexone derivatives provided by the present invention are described in detail below in the following embodiments.
[0059] For the preparation of the compounds involved in the present invention, see the literature (Portoghese, P. S.; Nagase, H.; Takemori, A.E. Stereochemical Studies on Medicinal Agents. 31. Only One Pharmacophore Is Required for the K-Opioid Antagonist Selectivity of Norbinaltorphimine. Journal of Medicinal Chemistry, 31 (1988), 1344- 1347).
[0060] Embodiment 1
[0061] (1) BV-2 microglia were cultured in an incubator at 37°C (containing 5% carbon dioxide). Medium: DMEM + 10% FBS; when cell density reaches 90% full plate rate, passaging conducted. BV-2 microglia were resuspended in medium (cell density: 2 MO5 cells/ml), plate in 96-well plate overnight. Medium replaced with DMEM without FBS, add 200ng/ml LPS and different concentrations of inhibitors (formula (I), formula (II), or formula (III)). After 24 hours, the supernatant was collected. The concentration of nitric oxide was determined by the 2,3-diaminonaphthalene fluorescence method.
[0062] Embodiment 1 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are shown in Figure 1 and Figure 2, where Figure 1 depicts the inhibitory effect of binary naltrexone derivatives on the activation of the TLR4 signaling pathway in BV-2 microglia in embodiment 1 of the present invention; Figure 2 depicts the inhibitory effect of binary naltrexone derivatives on the activation of the TLR4 signaling pathway in BV-2 microglia in embodiment 1 of the present invention.
[0063] As shown in Figure 1 and Figure 2, the inhibitors formula (II) and formula (III) can inhibit the release of nitric oxide, and the inhibitory activities are for formula (II) (4.7 ± 0.48 mM) and formula (III) (6.23± 1.82mM). Formula (I) has no significant inhibitory activity.
[0064] Embodiment 2
[0065] (2) BV-2 microglia were cultured in an incubator at 37°C (containing 5% carbon dioxide). Medium: DMEM + 10% FBS; when cell density reaches 90% full plate rate, passaging conducted. BV-2 microglia resuspended in medium (cell density: 2 MO5 cells/ml), plate in 96-well plate overnight. Replace medium with DMEM without FBS, add 200mg/ml LPS and different concentrations of inhibitors (formula (II) or formula (I)) for 24 hours. TNF-a and IL-1B levels in the supernatant due to TLR signaling pathway activation tested for using the commercial ELISA kit (BD Biosciences).
[0066] Embodiment 2 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are as shown in Figure 3 and Figure 4, where Figure 3 depicts the inhibitory effect of binary naltrexone derivatives on inflammatory factor TNF-a expression in BV-2 microglia in embodiment 2 of the present invention
F binary naltrexone derivatives; Figure 4 depicts the inhibitory effect of binary naltrexone derivatives on inflammatory factor IL-1B expression in BV-2 microglia in embodiment 2 of the present invention.
[0067] As can be seen from Figure 3 and Figure 4, inhibitor formula (II) described in the present invention can significantly inhibit inflammatory factor expression. Formula (I) has no significant inhibitory effect.
[0068] Embodiment 3
[0069] (3) Primary microglia were cultured in an incubator at 37°C (containing 5% carbon dioxide). Medium: DMEM + 10% FBS; when cell density reaches 90% full plate rate, passaging conducted. Primary microglia were resuspended in medium (cell density: (cell density: 2M0 cells/ml), plate in 96-well plate overnight. Medium replaced with DMEM without FBS, add 200ng/ml LPS and different concentrations of inhibitors (formula (II) or formula (I)). After 24 hours, the supernatant was collected. The concentration of nitric oxide was determined by the 2,3-diaminonaphthalene fluorescence method.
[0070] Embodiment 3 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are as shown in Figure 5, where Figure 5 depicts the inhibitory effect of binary naltrexone derivatives on TLR4 signaling pathway activation in primary microglia in embodiment 3 of the present invention;
[0071] As can be seen in Figure 5, inhibitor (II) described in the present invention can significantly inhibit nitric oxide release. Formula (I) has no significant inhibitory activity.
[0072] Embodiment 4
[0073] (4) Primary microglia were cultured in an incubator at 37°C (containing 5% carbon dioxide). Medium: DMEM + 10% FBS; when cell density reaches 90% full plate rate, passaging conducted. BV-2 microglia resuspended in medium (cell density: 2 MO5 cells/ml), plate in 96-well plate overnight. Replace medium with DMEM without FBS, add 200mg/ml LPS and different concentrations of inhibitors (formula (II) or formula (I)) for 24 hours. TNF-a levels in the supernatant due to TLR signaling pathway activation tested for using the commercial ELISA kit (BD Biosciences).
[0074] Embodiment 4 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. Figure 6 depicts the effect of binary naltrexone derivatives on inflammatory factor TNF-a expression in primary microglia in embodiment 4 of the present invention.
[0075] As can be seen in Figure 6, the inhibitor formula (II) described in the present invention can significantly inhibit inflammatory factor expression. Formula (I) has no significant inhibitory effect.
[0076] Embodiment 5
[0077] (5) Primary astrocytes were cultured in an incubator at 37°C (containing 5% carbon dioxide). Medium: DMEM + 10% FBS; when cell density reaches 90% full plate rate, passaging conducted. Primary microglia were resuspended in medium (cell density: (cell density: 2M0 cells/ml), plate in 96-well plate overnight. Medium replaced with DMEM without FBS, add 200ng/ml LPS and different concentrations of inhibitors (formula (II) or formula (I)). After 24 hours, the supernatant was collected. The concentration of nitric oxide was determined by the 2,3-diaminonaphthalene fluorescence method.
[0078] Embodiment 5 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are as shown in Figure 7. Figure 7 depicts the inhibitory effect of binary naltrexone derivatives formula (II) on TLR4 signaling pathway activation in primary astrocytes in embodiment 5 of the present invention.
[0079] As can be seen in Figure 7, the inhibitor formula (II) described in the present invention can significantly inhibit the release of nitric oxide. Formula (I) has no significant inhibitory activity.
[0080] Embodiment 6
[0081] (6) Primary astrocytes were cultured in an incubator at 37°C (containing 5% carbon dioxide). Medium: DMEM + 10% FBS. when cell density reaches 90% full plate rate, passaging conducted. BV-2 microglia resuspended in medium (cell density: 2 MO5 cells/ml), plate in 96-well plate overnight. Replace medium with DMEM without FBS, add 200mg/ml LPS and different concentrations of inhibitors (formula (II) or formula (I)) for 24 hours. TNF-a levels in the supernatant due to TLR signaling pathway activation tested for using the commercial ELISA kit (BD Biosciences).
[0082] Embodiment 6 of the present invention characterizes the inhibitory activity of binary naltrexone derivatives. The results are as shown in Figure 8. Figure 8 depicts the effect of binary naltrexone derivatives formula (II) on inflammatory factor TNF-a expression in primary astrocytes in embodiment 6 of the present invention.
[0083] As can be seen in Figure 8, inhibitor formula (II) described in the present invention can significantly inhibit inflammatory factor expression. Formula (I) has no significant inhibitory effect. [0084] The above description is only a preferred embodiment of the present invention, and it should be noted that those skilled in the art can make several improvements and refinements without departing from the principles of the present invention. These improvements and refinements should also be considered as the scope of protection of the present invention.

Claims

Claims
1. The application of binary naltrexone derivatives in the preparation of TLR4 signaling pathway inhibitors.
2. The application of binary naltrexone derivatives in the preparation of inflammatory factor expression inhibitors.
3. Based on the application described in claim 2, wherein the described inflammatory factor includes one or more of TNF-a and IL-1B.
4. The application of application of binary naltrexone derivatives in the preparation of inflammatory signaling pathway activation inhibitors.
5. Based on the applications described in claims 1-4, wherein the described inhibitors are used to inhibit TLR4 signaling pathway activation, inflammatory factor expression or nitric oxide release by LPS.
6. Based on any one of the applications described in claims 1-4, characterized in that the described binary naltrexone derivatives are as shown in formula (I), formula (II), or formula (III).
Figure imgf000011_0001
Formula (III)
7. The application of binary naltrexone derivatives in the preparation of drags for the prevention of autoimmune diseases, cancers, cardiovascular disease, drag addiction or neuropathic pain.
8. Based on the application described in claim 7, characterized in that the autoimmune diseases include systemic lupus erythematosus, and rheumatoid arthritis, and the cancers include lung cancer, breast cancer, and ovarian cancer.
9. A drag for controlling autoimmune disease, cancer, cardiovascular disease, drag addiction, or neuropathic pain, which comprises a binary naltrexone derivative and a pharmaceutically acceptable excipient.
10. Based on the drag described in claim 9, characterized in that the pharmaceutical dosage form comprises one of an injection preparation, an oral preparation, and a spray preparation.
PCT/US2019/062808 2018-11-23 2019-11-22 Application of binary naltrexone derivatives Ceased WO2020107015A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811405660.2 2018-11-23
CN201811405660.2A CN109288840A (en) 2018-11-23 2018-11-23 Application of Binary Naltrexone Derivatives

Publications (1)

Publication Number Publication Date
WO2020107015A1 true WO2020107015A1 (en) 2020-05-28

Family

ID=65144483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/062808 Ceased WO2020107015A1 (en) 2018-11-23 2019-11-22 Application of binary naltrexone derivatives

Country Status (2)

Country Link
CN (1) CN109288840A (en)
WO (1) WO2020107015A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109288840A (en) * 2018-11-23 2019-02-01 中国科学院长春应用化学研究所 Application of Binary Naltrexone Derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136845A1 (en) * 2009-07-16 2011-06-09 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
US20130345251A1 (en) * 2005-07-21 2013-12-26 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids and methods of use thereof
US20180147201A1 (en) * 2016-10-31 2018-05-31 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
CN109288840A (en) * 2018-11-23 2019-02-01 中国科学院长春应用化学研究所 Application of Binary Naltrexone Derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
WO2016160715A1 (en) * 2015-03-27 2016-10-06 Markel Dan Method for treating addiction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130345251A1 (en) * 2005-07-21 2013-12-26 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids and methods of use thereof
US20110136845A1 (en) * 2009-07-16 2011-06-09 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
US20180147201A1 (en) * 2016-10-31 2018-05-31 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
CN109288840A (en) * 2018-11-23 2019-02-01 中国科学院长春应用化学研究所 Application of Binary Naltrexone Derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG ET AL.: "Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling", THE FASEB JOURNAL, vol. 33, 1 August 2019 (2019-08-01), pages 9577 - 9587, Retrieved from the Internet <URL:https://www.fasebj.org/doi/pdf/10.1096/fj.201900173RRR> [retrieved on 20200220] *

Also Published As

Publication number Publication date
CN109288840A (en) 2019-02-01

Similar Documents

Publication Publication Date Title
Sprouse-Blum et al. Understanding endorphins and their importance in pain management
Deng et al. α2δ-1–Bound NMDA Receptors Mediate Morphine-induced Hyperalgesia and Analgesic Tolerance by Potentiating Glutamatergic Input in Rodents
Benson et al. A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models
US10301630B2 (en) Methods and compositions for unsilencing imprinted genes
Lesniak et al. Opioid peptides in peripheral pain control
Zhang et al. Opiate and acetylcholine-independent analgesic actions of crotoxin isolated from crotalus durissus terrificus venom
EP3349754B1 (en) Pcna inhibitors
AU2013357308B2 (en) Compositions comprising vortioxetine and donepezil
CN102078327B (en) Use of propargyl cysteine in the preparation of medicines for treating Alzheimer&#39;s disease
Ardianto et al. Opioid systems in the lateral hypothalamus regulate feeding behavior through orexin and GABA neurons
JP7166021B2 (en) Use of dopamine beta-hydroxylase (DBH) inhibitors and serotonin receptor (5-HT) antagonists for the treatment of cancer
Dondio et al. Non-peptide δ opioid agonists and antagonists (Part II)
Jiang et al. Spinal neuronal NOS signaling contributes to morphine cardioprotection in ischemia reperfusion injury in rats
Fiorino et al. Muscarinic pain pharmacology: realizing the promise of novel analgesics by overcoming old challenges
WO2020056109A1 (en) Combination cancer therapies
WO2011134075A1 (en) Sox9 inhibitors
WO2020107015A1 (en) Application of binary naltrexone derivatives
EP3965769B1 (en) Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer&#39;s disease
JP7244992B2 (en) Combinations of opioids and N-acylethanolamines
Wolfson et al. Enhancing FTS (Salirasib) efficiency via combinatorial treatment
Yang et al. Oxysophoridine through intrathecal injection induces antinociception and increases the expression of the GABAAα1 receptor in the spinal cord of mice
CA2921036A1 (en) Use of trichostatin a in the treatment of cancer
He et al. Supraspinal inhibitory effects of chimeric peptide MCRT on gastrointestinal motility in mice
Joun et al. Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma
Pol et al. Antisense oligodeoxynucleotides to μ-and δ-opioid receptor mRNA block the enhanced effects of opioids during intestinal inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19887793

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19887793

Country of ref document: EP

Kind code of ref document: A1